| 发明名称 |
DOSAGE FORM OF RECOMBINANT HUMANIZED MONOCLONAL ANTIBODY 2C4 |
| 摘要 |
Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER/2/HER1 and/or HER2/HER3 heterodimers and/or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4. |
| 申请公布号 |
CA2490758(C) |
申请公布日期 |
2014.09.23 |
| 申请号 |
CA20032490758 |
申请日期 |
2003.07.11 |
| 申请人 |
GENENTECH, INC.;F. HOFFMANN-LA ROCHE AG |
发明人 |
KOLL, HANS;BOSSENMAIER, BIRGIT;MULLER, HANS-JOACHIM;SLIWKOWSKI, MARK X.;KELSEY, STEPHEN MICHAEL |
| 分类号 |
A61K39/395;C07K14/485;A61P35/00;C07K16/28;C07K16/30;C07K16/32;G01N33/50;G01N33/53;G01N33/574 |
主分类号 |
A61K39/395 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
|
| 地址 |
|
